Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P51157
UPID:
RAB28_HUMAN
Alternative names:
-
Alternative UPACC:
P51157; G8JLC5; Q8IYR8; Q8NI05
Background:
Ras-related protein Rab-28, encoded by the gene with accession number P51157, plays a crucial role in cellular processes. Although its specific functions are yet to be fully elucidated, its involvement in the cellular machinery underscores its importance in maintaining cellular integrity and function.
Therapeutic significance:
Ras-related protein Rab-28 has been linked to Cone-rod dystrophy 18, a retinal dystrophy characterized by early loss of vision due to degeneration of cone photoreceptors. Understanding the role of Ras-related protein Rab-28 could pave the way for novel therapeutic strategies targeting this debilitating disease.